Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free KMTS Stock Alerts

Kestra Medical Technologies (KMTS) Competitors

Kestra Medical Technologies logo
$24.61 +0.43 (+1.78%)
Closing price 07/15/2026 04:00 PM Eastern
Extended Trading
$24.62 +0.00 (+0.02%)
As of 07/15/2026 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KMTS vs. BLCO, STVN, LIVN, MMED, and NVST

Should you buy Kestra Medical Technologies stock or one of its competitors? MarketBeat compares Kestra Medical Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kestra Medical Technologies include Bausch + Lomb (BLCO), Stevanato Group (STVN), LivaNova (LIVN), MiniMed Group (MMED), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does Kestra Medical Technologies compare to Bausch + Lomb?

Kestra Medical Technologies (NASDAQ:KMTS) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Kestra Medical Technologies has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kestra Medical Technologies$95.13M15.10-$113.81M-$3.96N/A
Bausch + Lomb$5.10B1.14-$360M-$0.62N/A

11.1% of Bausch + Lomb shares are held by institutional investors. 3.6% of Kestra Medical Technologies shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kestra Medical Technologies presently has a consensus target price of $27.83, indicating a potential upside of 13.10%. Bausch + Lomb has a consensus target price of $18.00, indicating a potential upside of 10.57%. Given Kestra Medical Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kestra Medical Technologies is more favorable than Bausch + Lomb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Bausch + Lomb
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21

Kestra Medical Technologies has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Kestra Medical Technologies had 10 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Kestra Medical Technologies and 7 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.47 beat Kestra Medical Technologies' score of 0.03 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kestra Medical Technologies
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bausch + Lomb
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bausch + Lomb has a net margin of -4.21% compared to Kestra Medical Technologies' net margin of -138.35%. Bausch + Lomb's return on equity of 3.60% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kestra Medical Technologies-138.35% -60.60% -43.21%
Bausch + Lomb -4.21%3.60%1.69%

Summary

Bausch + Lomb beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does Kestra Medical Technologies compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Kestra Medical Technologies (NASDAQ:KMTS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Kestra Medical Technologies had 16 more articles in the media than Stevanato Group. MarketBeat recorded 17 mentions for Kestra Medical Technologies and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.73 beat Kestra Medical Technologies' score of 0.03 indicating that Stevanato Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stevanato Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Kestra Medical Technologies
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Stevanato Group has a net margin of 11.76% compared to Kestra Medical Technologies' net margin of -138.35%. Stevanato Group's return on equity of 10.27% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group11.76% 10.27% 6.08%
Kestra Medical Technologies -138.35%-60.60%-43.21%

Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group€1.34B4.38€158.21M€0.5932.91
Kestra Medical Technologies$95.13M15.10-$113.81M-$3.96N/A

Kestra Medical Technologies has a consensus price target of $27.83, suggesting a potential upside of 13.10%. Given Kestra Medical Technologies' higher probable upside, analysts plainly believe Kestra Medical Technologies is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.83
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Stevanato Group beats Kestra Medical Technologies on 11 of the 15 factors compared between the two stocks.

How does Kestra Medical Technologies compare to LivaNova?

Kestra Medical Technologies (NASDAQ:KMTS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Kestra Medical Technologies has higher earnings, but lower revenue than LivaNova. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kestra Medical Technologies$95.13M15.10-$113.81M-$3.96N/A
LivaNova$1.39B3.14-$242.47M$1.9540.72

Kestra Medical Technologies has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

97.6% of LivaNova shares are owned by institutional investors. 3.6% of Kestra Medical Technologies shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Kestra Medical Technologies had 14 more articles in the media than LivaNova. MarketBeat recorded 17 mentions for Kestra Medical Technologies and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Kestra Medical Technologies' score of 0.03 indicating that LivaNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kestra Medical Technologies
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
LivaNova
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

LivaNova has a net margin of 7.48% compared to Kestra Medical Technologies' net margin of -138.35%. LivaNova's return on equity of 16.48% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kestra Medical Technologies-138.35% -60.60% -43.21%
LivaNova 7.48%16.48%7.59%

Kestra Medical Technologies currently has a consensus price target of $27.83, indicating a potential upside of 13.10%. LivaNova has a consensus price target of $81.38, indicating a potential upside of 2.47%. Given Kestra Medical Technologies' higher possible upside, equities analysts clearly believe Kestra Medical Technologies is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
LivaNova
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

LivaNova beats Kestra Medical Technologies on 11 of the 16 factors compared between the two stocks.

How does Kestra Medical Technologies compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Kestra Medical Technologies (NASDAQ:KMTS) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

19.7% of MiniMed Group shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by company insiders. Comparatively, 3.6% of Kestra Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kestra Medical Technologies has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$3.10B1.40-$190.97M-$0.68N/A
Kestra Medical Technologies$95.13M15.10-$113.81M-$3.96N/A

MiniMed Group currently has a consensus price target of $21.33, indicating a potential upside of 38.35%. Kestra Medical Technologies has a consensus price target of $27.83, indicating a potential upside of 13.10%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than Kestra Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Kestra Medical Technologies had 11 more articles in the media than MiniMed Group. MarketBeat recorded 17 mentions for Kestra Medical Technologies and 6 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.68 beat Kestra Medical Technologies' score of 0.03 indicating that MiniMed Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kestra Medical Technologies
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiniMed Group has a net margin of 0.00% compared to Kestra Medical Technologies' net margin of -138.35%. MiniMed Group's return on equity of 0.00% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
Kestra Medical Technologies -138.35%-60.60%-43.21%

Summary

MiniMed Group beats Kestra Medical Technologies on 10 of the 15 factors compared between the two stocks.

How does Kestra Medical Technologies compare to Envista?

Kestra Medical Technologies (NASDAQ:KMTS) and Envista (NYSE:NVST) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Envista has a net margin of 2.41% compared to Kestra Medical Technologies' net margin of -138.35%. Envista's return on equity of 7.11% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kestra Medical Technologies-138.35% -60.60% -43.21%
Envista 2.41%7.11%3.91%

Envista has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kestra Medical Technologies$95.13M15.10-$113.81M-$3.96N/A
Envista$2.81B1.55$47M$0.4165.14

Kestra Medical Technologies has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Envista has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Kestra Medical Technologies currently has a consensus target price of $27.83, suggesting a potential upside of 13.10%. Envista has a consensus target price of $28.54, suggesting a potential upside of 6.86%. Given Kestra Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Kestra Medical Technologies is more favorable than Envista.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Envista
0 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, Kestra Medical Technologies had 13 more articles in the media than Envista. MarketBeat recorded 17 mentions for Kestra Medical Technologies and 4 mentions for Envista. Envista's average media sentiment score of 0.75 beat Kestra Medical Technologies' score of 0.03 indicating that Envista is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kestra Medical Technologies
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Envista
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Envista beats Kestra Medical Technologies on 10 of the 14 factors compared between the two stocks.

Get Kestra Medical Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for KMTS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KMTS vs. The Competition

Export
MetricKestra Medical TechnologiesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.41B$8.39B$6.78B$12.56B
Dividend YieldN/A2.58%2.68%9.45%
P/E Ratio-10.1715.5127.1224.35
Price / Sales15.107.72487.6376.59
Price / CashN/A18.0148.6360.00
Price / Book6.153.3310.826.31
Net Income-$113.81M$228.19M$3.59B$331.55M
7 Day Performance-7.79%-2.50%-1.81%-0.71%
1 Month Performance27.98%-1.91%3.71%0.16%
1 Year Performance60.33%-0.34%27.41%19.66%

Kestra Medical Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KMTS
Kestra Medical Technologies
1.3225 of 5 stars		$24.61
+1.8%		$27.83
+13.1%		+51.1%$1.41B$95.13MN/A300
BLCO
Bausch + Lomb
3.6678 of 5 stars		$16.24
-2.9%		$18.00
+10.8%		+18.7%$5.97B$5.10BN/A13,000
STVN
Stevanato Group
2.7181 of 5 stars		€19.63
-0.6%		N/A-24.5%€5.94B€1.34B33.266,010
LIVN
LivaNova
1.9756 of 5 stars		$82.56
+0.0%		$80.75
-2.2%		+82.8%$4.53B$1.39B42.343,300
MMED
MiniMed Group
2.6614 of 5 stars		$15.29
+1.6%		$21.33
+39.5%		N/A$4.29B$3.10BN/A8,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KMTS) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
What will Nvidia do next?
Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...
TradeSmith | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
BlackRock just moved $150 billion into this "new internet"
BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...
Awesomely, LLC | Sponsoredtc pixel
$30M Could Unlock $500M in Metal
A small exploration company is sitting on an estimated $500 million worth of antimony - a critical defense met...
i2i Marketing Group, LLC | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel